EMA/418757/2021

European Medicines Agency decision

P/0365/2021

of 8 September 2021

on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), (EMEA-002012-PIP01-16-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0365/2021

of 8 September 2021

on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), (EMEA-002012-PIP01-16-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0155/2017 issued on 2 June 2017, the decision P/0210/2018 issued on 17 July 2018 and the decision P/0425/2019 issued on 4 December 2019,

Having regard to the application submitted by Lupin Europe GmbH on 15 April 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 July 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), capsule, hard, oral solution, oral use, gastric use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Lupin Europe GmbH, Hanauer Landstrasse 139-143, 60314 - Frankfurt, Germany.

EMA/PDCO/253034/2021
Amsterdam, 23 July 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002012-PIP01-16-M03

Scope of the application

Active substance(s):

Mexiletine (hydrochloride)

Invented name:

Namuscla

Condition(s):

Treatment of myotonic disorders

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Capsule, hard

Oral solution

Route(s) of administration:

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Lupin Europe GmbH

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Lupin Europe GmbH submitted to the European Medicines Agency on 15 April 2021 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0155/2017 issued on 2 June 2017, the decision P/0210/2018 issued on 17 July 2018 and the decision P/0425/2019 issued on 4 December 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 25 May 2021.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition

Treatment of myotonic disorders

2.1.1. Indication(s) targeted by the PIP

Symptomatic treatment of myotonic disorders

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

Oral solution

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1** Development of age appropriate solid formulation (capsule, not containing erythrosine as colorant) in lower strengths appropriate to the paediatric population **Study 2** *This study was deleted as a result of procedure EMEA-002012-PIP01-16-M03.*
Non-clinical studies	1	**Study 3** 11-week toxicity study in juvenile rats with a 4-week recovery period
Clinical studies	3	**Study 4** Open-label, non-comparative study to evaluate the PK, safety and efficacy of mexiletine in children and adolescents 6 to less than 18 years of age with clinical symptoms or signs of myotonic disorders (MEX-NM-301, EudraCT number 2019-003757-28) **Study 5** Prospective, long-term observational study (registry) of

		paediatric myotonic disorder patients from birth to less than 6 years of age who are treated with mexiletine (MEX-NM-401) **Study 6** *This study was deleted as a result of procedure EMEA-002012-PIP01-16-M01.* **Study 7** Open-label follow-up study evaluating the long-term safety and efficacy of mexiletine in children with myotonic disorders who have completed the initial paediatric studies (MEX-NM-303, EudraCT number 2019-003758-97)
Extrapolation, modelling and simulation studies	1	**Study 8** PK modelling study to support dosing recommendations in children
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of myotonic disorders

Authorised indication(s):

- Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders

Authorised pharmaceutical form(s):

Hard capsule (capsule)

Authorised route(s) of administration:

Oral use